Zuzanna Kandula

Poznan, WP, Poland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Genomic characterization of resistant and relapsed adult B-cell acute lymphoblastic leukemia.

Genomic characterization of resistant and relapsed adult B-cell acute lymphoblastic leukemia.

Journal: Journal of applied genetics
Published: October 27, 2025

Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study.

Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study.

Journal: American journal of hematology
Published: June 23, 2025

Inotuzumab therapy resulted in molecular remission of relapsed/resistant B-cell acute lymphoblastic leukemia with BCR::ABL1 Lys404Glu mutation.

Inotuzumab therapy resulted in molecular remission of relapsed/resistant B-cell acute lymphoblastic leukemia with BCR::ABL1 Lys404Glu mutation.

Journal: Annals of hematology
Published: November 26, 2024

Early intervention prevented intrauterine fetus death due to placental abruption in woman with JAK2V617F mutation-positive essential thrombocythemia.

Early intervention prevented intrauterine fetus death due to placental abruption in woman with JAK2V617F mutation-positive essential thrombocythemia.

Journal: Ginekologia polska
Published: June 28, 2024

High molecular risk variants, severe thrombocytopenia and large unstained cells count affect the outcome in primary myelofibrosis.

High molecular risk variants, severe thrombocytopenia and large unstained cells count affect the outcome in primary myelofibrosis.

Journal: Journal of applied genetics
Published: June 11, 2023

The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure.

The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure.

Journal: Leukemia research
Published: January 23, 2023

BCR::ABL1-like acute lymphoblastic leukaemia: a single institution experience on identification of potentially therapeutic targetable cases.

BCR::ABL1-like acute lymphoblastic leukaemia: a single institution experience on identification of potentially therapeutic targetable cases.

Journal: Molecular cytogenetics
Published: November 25, 2022

Clinical outcomes of therapy-related acute myeloid leukemia: an over 20-year single-center retrospective analysis.

Clinical outcomes of therapy-related acute myeloid leukemia: an over 20-year single-center retrospective analysis.

Journal: Polish archives of internal medicine
Published: September 27, 2022

Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.

Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.

Journal: Annals of hematology
Published: July 16, 2022

HRAS mutation positive multiple myeloma in the type 2 CALR mutation positive essential thrombocythemia: A case report.

HRAS mutation positive multiple myeloma in the type 2 CALR mutation positive essential thrombocythemia: A case report.

Journal: Journal of cellular and molecular medicine
Published: July 12, 2022

JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.

JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.

Journal: Journal of cancer research and clinical oncology
Published: June 14, 2022

Mutations in the miR-142 gene are not common in myeloproliferative neoplasms.

Mutations in the miR-142 gene are not common in myeloproliferative neoplasms.

Journal: Scientific reports
Published: March 11, 2022
Showing 1-12 of 19

Last Updated: 09/26/2026